Mayne Pharma Faces Scrutiny Over Cosette Acquisition
Mayne Pharma Group Limited (ASX: MYX) is facing challenges in its proposed acquisition by Cosette Pharmaceuticals, Inc.
The company, focused on commercialising novel pharmaceuticals and providing contract development and manufacturing services, received a letter indicating the Treasurer's preliminary view that the acquisition would be contrary to the national interest.
The acquisition would be contrary to the national interest, citing a negative impact on the Australian economy and community.
Author's summary: Mayne Pharma's acquisition faces national interest concerns.
More News
- SNAP Rules November 2025: Changes and eligibility criteria for food stamps updated
- The unexpected reaction of Tyreek Hill after the firing of Dolphins general manager Chris Grier
- Trump Administration Admits It Doesn’t Know Who Exactly It’s Killing in Boat Strikes
- Amazon’s newest streaming stick is missing a Spotify app.
- Jerry Jones needs to learn from Carlie Irsay-Gordon if he wants the Cowboys to win the Super Bowl